Josee Hamelin
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Corrigendum to "PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease" [Metabolism Volume 150, January 2024, 155736, PMID: 7967646].
Journal: Metabolism: clinical and experimental
Published: September 19, 2024
PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease.
Journal: Metabolism: clinical and experimental
Published: April 21, 2023
Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 26, 2019
Proprotein convertase 7 (PCSK7) reduces apoA-V levels.
Journal: The FEBS journal
Published: August 07, 2019
HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin.
Journal: Cell death and differentiation
Published: July 25, 2018
New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.
Journal: Scientific reports
Published: October 18, 2017
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation.
Journal: The Journal of biological chemistry
Published: December 18, 2016
The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Journal: The Journal of biological chemistry
Published: November 24, 2016
Breast metastases from lung cancers with the EGFR mutation
Journal: Revue des maladies respiratoires
Published: February 21, 2016
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Journal: The Journal of biological chemistry
Published: January 27, 2016
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Journal: The Journal of biological chemistry
Published: February 23, 2015
Last Updated: 09/26/2026